Charles River Laboratories International, Inc. filings document the company’s operating results, material events, governance matters, and capital-structure disclosures as a New York Stock Exchange-listed issuer with common stock trading under CRL. Form 8-K reports cover quarterly and annual financial results, guidance, share repurchase activity, completed portfolio changes, conference disclosures, and executive appointment and compensation matters.
Proxy materials describe shareholder voting matters, board elections, executive compensation, equity incentive plans, and auditor ratification. The filing record also reflects disclosure categories tied to the company’s drug discovery and development services, including segment performance for Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions, along with forward-looking risk language and compliance matters.
Shannon M. Parisotto, CEVP, Disc & Safety Assessment at Charles River Laboratories International, Inc., exercised options to acquire 981 common shares at $208.44 per share and sold 981 shares at $308.44 per share on October 5, 2026. The exercise and sale occurred under a Rule 10b5-1 Trading Plan adopted March 4, 2026. After the exercise, 2,944 stock options remained. Reported indirect holdings included 9,680 common shares held by Trust and 28,510 common shares held by Karpathos Investments LLC.
Charles River Laboratories International, Inc. officer Shannon M. Parisotto reported a proposed sale of 981 common shares, with an approximate sale date of October 5, 2026, through UBS Financial Services, Inc. The stated aggregate market value is $308,579.64. The shares are listed as acquired from the issuer by exercising stock options, with cash payment.
Charles River Laboratories International, Inc. EVP & Chief Financial Officer Glenn Coleman purchased 10 shares of common stock at $297.43 per share on September 30, 2026, through the Company's Employee Stock Purchase Plan at fair market value on the purchase date. He held 27,762 shares directly following the purchase. Coleman elected to participate during an open trading window before the quarterly purchase period began; no Rule 10b5-1 plan is reported.
Charles River Laboratories International, Inc. reaffirmed its 2026 guidance at Investor Day, saying revenue and non-GAAP earnings per share are expected at the upper ends of prior ranges. The guidance lists organic revenue growth at the upper end of 0%–1%, non-GAAP operating margin of 21.0%–21.3%, and non-GAAP earnings per share at the upper end of $11.15–$11.45.
Its Pathway to Purpose strategy focuses on productivity and efficiency, scientific portfolio investments, and a customized client approach. For 2027–2030, its targets are 5%–7% organic revenue CAGR, approximately 24% non-GAAP operating margin, and low-double-digit non-GAAP earnings-per-share CAGR. The company expects its Create the Future program to generate over $300 million in cumulative savings from 2027 through 2030; bioanalysis revenue is expected to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. The Apollo platform serves more than 18,000 client users. The 2030 targets exclude future acquisitions and divestitures and are not projections or financial guidance; they are subject to significant uncertainties and contingencies and management assumptions that may change.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a significant shareholder reported on an amended Schedule 13G.
FMR LLC and Abigail P. Johnson report beneficial ownership of 4,865,628.13 shares of CRL common stock, representing 10.2% of the class as of August 31, 2026. FMR LLC reports sole voting power over 4,813,779.74 shares and sole dispositive power over 4,865,628.13 shares, with no shared voting or dispositive power. The filing notes that one or more other persons may have rights to receive dividends or sale proceeds from these shares, but no single other person’s interest exceeds five percent of CRL’s outstanding common stock.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) director James C. Foster reported an option exercise-and-sale transaction in the company’s common stock. On August 25, 2026, he exercised stock options covering 33,561 shares of common stock at exercise prices of $194.12 and $208.44 per share, receiving the underlying shares.
On the same date, he sold 33,561 shares of common stock at $300.00 per share in an open market or private transaction. According to the filing, this exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster also reports indirect holdings of common stock through several trusts and Grantor Retained Annuity Trusts.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for a planned resale of its common stock under Rule 144 by director James Foster. The notice covers 33,561 shares of common stock, with an aggregate market value of $10,065,950.73, relative to 47,738,872 shares outstanding as of August 25, 2026.
The shares are to be sold through UBS Financial Services, Inc. on the NYSE, in connection with an exercise of stock options for cash on August 25, 2026. Foster also reported prior sales in the past three months totaling 103,733 shares for combined proceeds of $24,776,575.00.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported an insider equity transfer by Chief Executive Officer and director Birgit Girshick. On 2026-08-19, Girshick made a bona fide gift of 528 shares of Common Stock, leaving 35,485 shares held directly and 43,803 shares held indirectly through a revocable trust.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) executive Shannon M. Parisotto, CEVP, Discovery & Safety Assessment, reported an option exercise-and-sale transaction. Parisotto exercised 2,039 stock options at an exercise price of $194.12 per share, acquiring 2,039 common shares, and then sold 2,039 common shares at $294.12 per share. The sale was made pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 4, 2026. Following these transactions, Parisotto reports indirect ownership of 9,680 common shares by a trust and 28,510 common shares through Karpathos Investments LLC, as shown in the holding entries.
For CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL), director Nancy C. Andrews reported an option exercise and same-day sale. She exercised 573 stock options at an exercise price of $164.30 per share, acquiring 573 shares of common stock, and then sold 573 common shares at $285.24 per share. After these transactions, she reported 3,964 common shares held indirectly by trust. The Rule 10b5-1 trading-plan box was not checked.